News|Articles|November 4, 2025

6 Hepatology Headlines You Missed in October 2025

Check out the latest episode of Liver Lineup on alcohol-associated liver disease, new data on resmetirom, hepatic headlines from ACG 2025, and more.

October 2025 saw several notable developments in hepatology, from a new episode of HCPLive’s Liver Lineup: Updates & Unfiltered Insights to new data on MASH risk and treatment as well as hepatic news from the American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting.

Related to this article

October 2nd, 2026

Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.

October 1st, 2026

As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.

October 7th, 2026

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

October 6th, 2026

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

October 6th, 2026

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

October 6th, 2026

Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.

October 5th, 2026

Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.

October 7th, 2026

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.